Immunotherapy + CRT Boosts Response in Esophageal Cancer ...Middle East

Medscape - News
Immunotherapy + CRT Boosts Response in Esophageal Cancer
The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with chemoradiotherapy alone in locally advanced ESCC. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Immunotherapy + CRT Boosts Response in Esophageal Cancer )

Also on site :